Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!

Juno Therapeutics Shows Promise With Non-Hodgkin Lymphoma Drug

Courtesy of Benzinga.

Juno Therapeutics Shows Promise With Non-Hodgkin Lymphoma Drug

Juno Therapeutics Inc (NASDAQ: JUNO) opened sharply higher after reporting third-quarter earnings after the close Wednesday.

The report highlighted ASH abstracts on JCAR017, a non-Hodgkin lymphoma drug, showing promising efficacy and solid safety in r/r DLBCL, Barclays analyst Gena Wang said in a note. Juno also reported that BLA filing is on track in the second half of 2018, and that a TRANSCEND study update demonstrated durable and consistent responses for JCAR017 in r/r DLBCL, “especially in the core patient group,” Wang said. (See Wang’s track record here.) 

Outpatient administration could potentially further differentiate JCAR017 from its competition, said Wang. Better understanding of the CRS profile and treatment course would provide valuable information on the feasibility of outpatient administration of the drug, the analyst said. 

Wang expects that pivotal trial initiation in the BCMA CAR-T program will start in the second half of 2018. The first phase of the trial should be initiated in early 2018, while phase two should start six months later, she said. BCMA CAR-T could further differentiate the company from the competition, the analyst said.

Initial clinical data from Juno’s solid tumor programs is expected in April 2018, Wang said. 

Barclays has an Overweight on Juno Therapeutics with a $55 price target. 

Related Links: 

Juno Therapeutics Adds To Monday’s Gain After Wedbush Upgrade

Lightning Round: Jim Cramer Weights In On Juno Therapeutics, Halliburton And More

Latest Ratings for JUNO

Date Firm Action From To
Nov 2017 Leerink Swann Maintains Outperform
Oct 2017 Morgan Stanley Maintains Equal-Weight
Sep 2017 Barclays Initiates Coverage On Overweight

View More Analyst Ratings for JUNO


View the Latest Analyst Ratings

Posted-In: Barclays Gena WangAnalyst Color Earnings News Health Care Analyst Ratings General Best of Benzinga


Do you know someone who would benefit from this information? We can send your friend a strictly confidential, one-time email telling them about this information. Your privacy and your friend's privacy is your business... no spam! Click here and tell a friend!





You must be logged in to make a comment.
You can sign up for a membership or get a FREE Daily News membership or log in

Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!